Evidence map›Paper›PMID 34855161›Full record

ArticleEuropean journal of drug metabolism and pharmacokinetics2022

Influence of Gegenqinlian Decoction on Pharmacokinetics and Pharmacodynamics of Atorvastatin Calcium in Hyperlipidemic Rats.

Mingyu Cui, Fengmei Zhu, Yifeng Yin, Yue Sui, Xueying Yan, Tingting Chen

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of drug metabolism and pharmacokinetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. TheFrontiers in pharmacology · 2024
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mingyu CuiCollege of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, 150040, China. cuimingyu1971@163.com.
Fengmei ZhuCollege of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, 150040, China.
Yifeng YinCollege of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, 150040, China.
Yue SuiCollege of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, 150040, China.
Xueying YanCollege of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, 150040, China.
Tingting ChenCollege of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, 150040, China.

Funding

the national science foundation of china No.81274034the national science foundation of heilongjiang province H2015044the national science foundation of heilongjiang province LH2020H096
6 · The paper itself

Abstract

BACKGROUND AND

objectivesGegenqinlian decoction (GQD), a classic traditional Chinese medicine (TCM), was described in Shanghan Lun. GQD is often combined with antihyperlipidemic drugs (mainly atrovastatin calcium) in TCM clinics. However, the herb-drug interaction between GQD and atrovastatin calcium (AC) is still unknown. To determine whether the combination is safe, we evaluated the effects of GQD on the activities of cytochrome P450 (CYP) 3A2 enzyme and investigated the impact of GQD on the pharmacokinetics and pharmacodynamics of AC in rats.

methodsThe pharmacokinetics of AC (10 mg/kg) with or without pretreatment with GQD (freeze-dried powder, 1.35 g/kg) were investigated using HPLC. The influence of GQD on pharmacodynamics of AC were determined by detecting the levels of serum total cholesterol (TC), triglycerides (TG), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), aspartate aminotransferase (AST) and alanine aminotransferase (ALT). Moreover, the probe drug method was used to explore the effect of GQD on CYP3A2 activity.

resultsThe pharmacokinetic parameters of AC combined with GQD were significantly affected (P < 0.05) in hyperlipidemic rats. The serum TC, TG and LDL-C levels of the combination were significantly reduced (P < 0.05), and the serum HDL-C level was significantly increased (P < 0.05) compared with AC/GQD alone. AST and ALT activities treated with both GQD and AC+GQD group were significantly reduced (P < 0.05) compared with AC group. There was a significant difference in the pharmacokinetic parameters of midazolam between control and GQD groups (P < 0.05). Maximum concentration (C

conclusionsThe result suggested that GQD combined with AC can improve the lipid-lowering effect of AC and reduce the damage of AC to the liver simultaneously. However, GQD can inhibit the activity of CYP3A2 in hyperlipidemic rats and increase the blood concentration of AC. Therefore, the clinical dose of AC should be adjusted when they are combined. Since the study was conducted in rats,  further research should be carried out to assess the uniformity of the pharmacokinetics and pharmacodynamics between rats and humans.

Indexed as

AnimalsArea Under CurveAtorvastatinDisease Models, AnimalDrugs, Chinese HerbalHerb-Drug InteractionsHydroxymethylglutaryl-CoA Reductase InhibitorsHyperlipidemiasMaleRandom AllocationRatsRats, Sprague-DawleyAtorvastatinDrugs, Chinese HerbalgegenqinlianHydroxymethylglutaryl-CoA Reductase Inhibitors

Identifiers

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.